Schram, Alison M.
Chang, Matthew T.
Jonsson, Philip
Drilon, Alexander
Article History
First Online: 31 August 2017
Competing interests
: A.D. has received honoraria from and is an advisory board member for Ariad, AstraZeneca, Blueprint Medicines, Exelixis, Genentech/Roche, Ignyta and Loxo Oncology and has received research funding from Foundation Medicine. The other authors declare no competing interests.